Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Foghorn Therapeutics

foghorntx.com

Latest From Foghorn Therapeutics

Finance Watch: Flagship Raises $824m To Speed Growth Of Its Portfolio Companies

Private Company Edition: The VC firm and start-up factory Flagship Pioneering brings in new cash for existing investments, tapping into investors eager to back "big, bold platform ideas" in the life sciences. Also, new financings include $100m-plus deals for Harmony and Beam.

Financing StartUps and SMEs

Venture Funding Deals: MedImmune Spinout Viela Lands $250m Series A

China's JW Therapeutics nets $90m for cancer cell therapy, including backing from biotechs Celgene and WuXi. Meanwhile, Foghorn sounds out a $50m A round for its gene trafficking technology applications.

Deals Financing
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Foghorn Therapeutics
  • Senior Management
  • Adrian Gottschalk, Pres. & CEO
    Allan Reine, MD, CFO
    Steve Bellon, MD, VP, Drug Discovery
    Carl P Decicco, PhD, CSO
    Samuel Agresta, MD, CMO
  • Contact Info
  • Foghorn Therapeutics
    100 Binney St.
    Ste. 610
    Cambridge, MA 02142
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register